Tag: email

Jeremy Garber Will Serve As Interim Chief Financial Officer

Revolutionizing Access to Modern Weight-Care Solutions

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Civitas Resources, Inc. (NYSE: CIVI) between February 27, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important July 1, 2025 lead plaintiff deadline.

SAN FRANCISCO, June 18, 2025 (GLOBE NEWSWIRE) -- Did you suffer substantial losses on your Napco Security Technologies (NASDAQ: NSSC) investments? Hagens Berman reminds investors of a critical deadline: June 24, 2025. This is your deadline for seeking appointment as lead plaintiff in a federal securities class action lawsuit against Napco.

NEW YORK and NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time.

Recognized for innovation and inclusion, Mosaicx debuts next-generation Engage platform and earns Best Workplace for Gender Equity Award

New ETF offers direct exposure to a digital asset used by global financial institutions for cross-border payments

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.